ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1440 • ACR Convergence 2022

    Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study

    Fatima Alduraibi1, Kathryn Sullivan1, Winn Walter Chatham2, Hui-Chen Hsu1 and John Mountz1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
  • Abstract Number: 1433 • ACR Convergence 2022

    A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

    Ulf Müller-Ladner1, Karl Gaffney2, Deepak Jadon3, Marco Matucci-Cerinic4, Eugenio Chamizo Carmona5 and Janet Addison6, 1JLU Campus KK, Bad Nauheim, Germany, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Cambridge University, Cambridge, United Kingdom, 4University of Florence, Florence, Italy, 5Hospital de Mérida, Mérida, Spain, 6Biogen Idec Ltd, Maidenhead, United Kingdom

    Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…
  • Abstract Number: 1446 • ACR Convergence 2022

    Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients

    Tarek Carlos Salman-Monte1, Patricia Corzo2, Ivan Garcia-Duitama3, ANA Agustí Claramunt3, Irene Carrion Barbera4, Salvatore Marsico3 and Jordi Monfort5, 1Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital del Mar, Radiology, Barcelona, Spain, 4Hospital del Mar, Rheumatology, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain

    Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
  • Abstract Number: 1447 • ACR Convergence 2022

    Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers

    Carolina Munoz1, Michelle Barraclough2, Juan Pablo Diaz-Martinez1, Jiandong Su1, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, May Choi6, Dennisse Bonilla1, Simone Appenzeller7, Patricia Katz8, Dorcas Beaton9, Robin Green5, Joan Wither10 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, São Paulo, Brazil, 8UCSF, San Rafael, CA, 9Institute for Work & Health, Toronto, ON, Canada, 10Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…
  • Abstract Number: 1436 • ACR Convergence 2022

    Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

    Mohaned Hameed1, Sofia Exarchou1, Anna Eberhard1, Ankita Sharma1, Ulf Bergström1, Jon Einarsson2 and Carl Turesson3, 1Lund University, Malmö, Sweden, 2Skåne University Hospital, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
  • Abstract Number: 1445 • ACR Convergence 2022

    Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India

    Pankti Mehta1, Akansha Srivastava2, Amita Aggarwal2, Liza Rajasekhar3, Vineetha Shobha4, Chengappa Kavadichanda5, ASHISH JACOB MATHEW6, Parasar Ghosh7, Bidyut Das8, Avinash Jain9, Ranjan Gupta10 and Manish Rathi11, 1King George's Medical University, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Nizam's Institute of Medical Sciences, Madhapur, India, 4St. John’s Medical College Hospital, Bangalore, India, 5JIPMER, Pondicherry, Puducherry, India, 6Christian Medical College, Vellore, Vellore, India, 7Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 8SCB medical college, Cuttack, India, 9SMS Medical College, Lucknow, India, 10All India Institute of Medical Sciences, New Delhi, India, 11PGIMER Chandigarh, Chandigarh, India

    Background/Purpose: Gastrointestinal (GI) manifestations of Systemic Lupus Erythematosus (SLE) although rare are often severe. These are difficult to directly attribute to SLE as they can…
  • Abstract Number: 1458 • ACR Convergence 2022

    Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment

    Delansie Lawrence1, Jiandong Su1, Andrea Knight2, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, Joan Wither6, May Choi7, Simone Appenzeller8, Nicole Anderson1, Dennisse Bonilla1, Patricia Katz9, Dorcas Beaton10, Robin Green5, Zahi Touma1 and Michelle Barraclough11, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 7Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 8Unicamp, Campinas, São Paulo, Brazil, 9UCSF, San Rafael, CA, 10Institute for Work & Health, Toronto, ON, Canada, 11Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
  • Abstract Number: 1452 • ACR Convergence 2022

    Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis

    James Sullivan1 and Emily Littlejohn2, 1Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
  • Abstract Number: 1454 • ACR Convergence 2022

    A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study

    Sarah Reid1, Johanna K Sandling1, Pascal Pucholt1, Ahmed Sayadi1, Christopher Sjöwall2, Karoline Lerang3, Andreas Jönsen4, Anders A Bengtsson4, Øyvind Molberg3, Anna Rudin5, Solbritt Rantapää-Dahlqvist6, Lars Ronnblom7 and Dag Leonard1, 1Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 4Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 6Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 7Uppsala University, Uppsala, Sweden

    Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
  • Abstract Number: 1450 • ACR Convergence 2022

    Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis

    KONSTANTINOS TSELIOS1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz4, 1McMaster University, Population Health Research Institute, Hamilton, ON, Canada, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
  • Abstract Number: 1461 • ACR Convergence 2022

    The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis

    Omer Pamuk1 and Sarfaraz Hasni2, 1NIH/NIAMS, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD

    Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
  • Abstract Number: 1460 • ACR Convergence 2022

    Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis

    Omer Pamuk1, Saja Ali2 and Sarfaraz Hasni2, 1NIH/NIAMS, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD

    Background/Purpose: The diagnosis of neuropsychiatric lupus (NPSLE) is challenging due to its variegated presentation, absence of diagnostic biomarkers and radiological imaging. The NPSLE is further…
  • Abstract Number: 1462 • ACR Convergence 2022

    Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis

    Samar Soliman1, Samantha Stanley2, Kamala Vanarsa2, Faten Ismail3, Chi Chiu Mok4 and Chandra mohan5, 1Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, 2Department of Biomedical Engineering, University of Houston, Houston, TX, 3Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, 4Tuen Mun Hospital, Hong Kong, China, 5University of Houston, Houston, TX

    Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
  • Abstract Number: 1403 • ACR Convergence 2022

    Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study

    Lucia Cristina Dominguez Casas1, Mª Paz Rodriguez Cundin2, Trinidad Dierssen Sotos3, Nuria Vegas Revenga4, Alfonso Corrales5, Miguel Ángel González-Gay6 and Ricardo Blanco7, 1Hospital Universtario San Agustin, Oviedo, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Universidad de Cantabria, Santander, Spain, 4Hospital Galdakao- Usansolo, Galdakao, Spain, 5Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 7Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…
  • Abstract Number: 1353 • ACR Convergence 2022

    Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study

    Domitille RENARD1, Sophie Tuffet2, Philippe Dieude3, Pascal Claudepierre4, Laure Gossec5, Bruno Fautrel6, Anna Molto7, Corinne MIceli8, Pascal Richette9, Emmanuel Maheu10, Claire Carette11, Sebastien Czernichow11, Chloe JAMAKORZYAN12, alexandra Rousseau2, Francis Berenbaum13, Catherine Beauvais14 and Jérémie SELLAM15, 1Sorbonne University Paris- Sant Antoine Hospital, Paris, France, 2Saint Antoine hospital, Paris, Ile-de-France, France, 3Université Paris Cité, Paris, France, 4Paris Est Creteil University, Creteil, France, 5Sorbonne Université, Paris, France, 6Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 7Rheumatology Department, Cochin Hospital, APHP, Paris, France, 8APHP, Paris, France, 9Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 10Hôpital Paris Saint Antoine, Moirans, Auvergne-Rhône-Alpes, France, 11Hôpital Européen Georges Pompidou, Paris, France, 12Hopital Begin, Saint-Mandé, France, 13Sorbonne University - Saint-Antoine hospital, Paris, France, 14Saint Antoine hospital, Paris, France, 15Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France

    Background/Purpose: Diet is a subject of questioning and beliefs among patients with rheumatic diseases. They are inclined to change their eating habits and sometimes follow…
  • « Previous Page
  • 1
  • …
  • 577
  • 578
  • 579
  • 580
  • 581
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology